Fundraising Fox
Neurogene
NASDAQ: NGNENew York, US · Founded 2018 · 7 known investors
Find your way into Neurogene
Sign up to see every warm intro you have to Neurogene
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Neurogene team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Neurogene develops gene therapy treatments for rare neurological diseases. The company aims to make severe genetic neurological conditions treatable for patients and families impacted by these conditions.
Founders & leadership
Neurogene was founded in 2018 by Rachel McMinn and Rachel McMinn, Ph.D..
Board
Investors · 7
How we know: pharmaceutical-technology.com · Not right? Tell us
How we know: Samsara BioCapital's portfolio page · board seat on SEC Form D · pharmaceutical-technology.com · Not right? Tell us
How we know: allsci.com · Not right? Tell us
How we know: allsci.com · Not right? Tell us
How we know: press coverage · Not right? Tell us
Also in the syndicate · 1
Funding
SEC filings, press & company announcements$231.5M disclosed across 3 of 4 rounds · 2019–2026
- $125Mpublic offeringJul 2026 · 2 sources
Casdin Capital, EcoR1 Capital, Redmile Group, RTW Investments
Source ↗
▶$69MraisedDec 2020 · 32 investors · OtherRule 506(b)
- Rachel McMinnExecutive Officer, Director
- Christine Mikail CvijicExecutive Officer
- Robert BaffiDirector
- Caroline StoutDirector
- Cory FreedlandDirector
- Srdjan StankovicDirector
- Stephen BiggarDirector
- Offering amount
- $115M
- Amount sold
- $69M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$37.5MraisedFeb 2019 · 13 investors · OtherRule 506(b)
- Cory FreedlandDirector
- Rachel McMinnExecutive Officer, Director
- Stephen BiggarDirector
- Offering amount
- $37.5M
- Amount sold
- $37.5M
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 4
Companies working in the same space as Neurogene.
In the news
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates - BioSpacebiospace.com · Aug 2026
Neurogene (NGNE) widens loss yet raises $134.8M to fund Rett trialstocktitan.net · Aug 2026Frequently asked questions
- What does Neurogene do?
- Neurogene develops gene therapy treatments for rare neurological diseases. The company aims to make severe genetic neurological conditions treatable for patients and families impacted by these conditions.
- Who founded Neurogene?
- Neurogene was founded by Rachel McMinn, Rachel McMinn, Ph.D. in 2018.
- Who are Neurogene's investors?
- Neurogene's investors include EcoR1 Capital, Samsara BioCapital, Casdin Capital, REDMILE, RTW Investments L.P., William Blair.
- How much funding has Neurogene raised?
- Neurogene has disclosed $231.5M raised across 3 of its 4 known rounds.
- Where is Neurogene headquartered?
- Neurogene is headquartered in New York, US.